Autosomal Dominant Polycystic Kidney Disease (ADPKD) Cystic Kidney Disease
Conditions
Interventions
The patients and healthy controls will undergo a standard water deprivation
test, based on van der Berg, Robertson and Farquhar. In summary, the patient
starts thirsting from 6 p.m. the day before t
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: The diagnosis of ADPKD will be assessed as routinely by the Ravine criteria, and ADPKD patients will be selected to be between 18 and 65 years of age, and stratified for eGFR, with 15 ADPKD patients having an eGFR 60 ml/min/1.73 m2.;The diagnosis IgA- or membranous nephropathy will be based upon clinical history and laboratory values, according to clinical practice. IgA- and membranous nephropathy patients will be selected to be between 18 and 65 years . IgA- and membranous nephropathy patients need to be in a stable disease phase of their disease, as defined by proteinuria 60 ml/min/1.73 m2, albuminuria less than 30 mg/d, absence of plasma electrolyte concentration abnormalities. Healthy volunteers will be selected to be between 18 and 65 years of age. ;The day before the water deprivation test urine will be collected and a vena punction will we done. We will use the vena punction to determine the eGFR and plasma electrolyte concentration abnormalities. A urine dipstick showing negative or trace is used to rule out albuminuria. We will have the results before the waterdeprivation test starts the next day.
Exclusion criteria
Exclusion criteria: ADPKD subjects, IgA- and membraneuze nephropathie subjects and healthy volunteers are excluded in case they use medication or have comorbidities that may affect urinary concentration capacity, medication being the use of diuretics or vasopressin receptor antagonists, and comorbity being diabetes mellitus (DM), diabetes insipidus or kidney disease other than ADPKD.;Other exclusion criteria are: - those diseases / factors that are known to influence vasopressin concentration: smoking, alcohol use of 4 or more consumptions per day, hypovolemia of any cause, deficiency of adrenal or thyroid hormone, pregnancy, menstruation at time of the water deprivation test or using postmenopausal hormone therapy (because estrogen influences AVP release). - active cardiovascular disease (angina pectoris). - urinary tract infection - incapabability of understanding the informed consent form, signing the consent or unability to comply with all requirements of the trial.;To gain more information about their eGFR, use of medication, comorbidities that may affect urinary concentration capacity and other exclusion criteria (active cardiovascular disease), ADPKD patients and IgA- and nephropathy patients will be asked for approval of insight in their medical records. This is not necessary for healthy volunteers, we will collect information about inclusion and exclusion criteria by anamnesis. We will not test any of the exclusion criteria otherwise besides an anamnesis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma AVP and copeptin levels in relation to maximum plasma osmolality and urinary osmolality. | — |
Countries
Netherlands
Outcome results
None listed